White House Report Identifies Precision Medicine for Future R & D Investment

Precision medicine was identified by a recent White House Office of Science and Technology Policy Report (“Report”) as a research and development priority for the United States over the next 20 years. The Report highlighted goals to advance precision medicine, including improvements in health monitoring, multi-omics, cell therapies, artificial intelligence-driven drug development, gene editing, microbial genome sequencing and synthetic biology.

Ten aspiration goals under five broad themes were selected to accelerate medical breakthroughs and advance human health in precision medicine. The five themes are:

Theme 1 - Accessible health monitoring to identify indicators of health and develop and distribute a simple-to-use home diagnostic assay kit to report health across the lifespan and meet the needs of diverse populations.

Theme 2 - Precision multi-omic medicine to collect multi-omic measures in large cohorts with diverse populations, as well as to develop molecular classifications for diagnosis and/or treatment and make these actionable with development of the $1,000 multi-ome.

Theme 3 - Biomanufacturing of cell-based therapies to expand the toolset of technologies used to create cell-based therapies to achieve high viability and targeted delivery at the time of patient administration, as well as expand access to cell-based therapies to decrease health inequities.

Theme 4 - AI-driven bioproduction of therapeutics to increase the speed and diversity of therapeutic manufacturing, including manufacture of current therapeutics as well as design of novel ones.

Theme 5 - Advanced techniques in gene editing to assess current gene-editing systems and emerging technologies for therapeutic gene editing as well as to strengthen the biomanufacturing ecosystem to produce millions of doses of therapeutic gene-editing systems annually.

Report at page 38.

A development and implementation plan to address the research and development needs outlined in the Report will be led by the Office of Science and Technology Policy.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.